Source link : https://www.newshealth.biz/health-news/significant-milestone-for-radionuclide-therapy-in-refractory-meningioma/
Use of an approved radionuclide therapy for difficult-to-treat meningioma was associated with substantially improved progression-free survival (PFS) compared with a historical benchmark, according to results of a small single-arm phase II trial. Among 20 patients with surgery- and radiation-refractory intracranial tumors, treatment with lutetium (Lu)-177 dotatate (Lutathera) was associated with a 6-month PFS rate three […]
Author : News Health
Publish date : 2024-10-02 21:41:21
Copyright for syndicated content belongs to the linked Source.